

AMENDMENTS TO THE CLAIMS

This listing replaces all versions and listings of claims in the application.

Listing of Claims

1 - 63. (Cancelled).

64. (Currently Amended) A composition for the treatment of dermal inflammation, comprising a combination of
(i) glyceryl monocaprylate or an alkali metal salt thereof and
(ii) niacinamide or a salt thereof,
wherein the component (i) and the component (ii) are present in a molar ratio of between about 1:3 and 1:16.

65-71. (Cancelled).

72. (Previously Presented) The composition according to claim 64, wherein the component (i) is racemic, enantiomerically enriched or enantiomerically pure 1-glyceryl-monocaprylate and wherein component (ii) is niacinamide.

73. (Currently Amended) The composition according to claim 64, further comprising one or more excipient(s) or carrier(s) for the formulation of a pharmaceutical, ~~a dietary supplement~~ or a cosmetic.

74. (Previously Presented) The composition according to claim 73, further comprising one or more therapeutically active agents.

75. (Currently Amended) The composition according to claim 73, formulated for ~~oral~~, topical, or transdermal, ~~or parenteral~~ administration.

76. (Previously Presented) The composition according to claim 75, formulated for topical administration.

77-93. (Cancelled)

94. (Currently Amended) The composition according to claim 72, wherein the 1-
glyceryl monocaprylate and the niacinamide[[,]] or a salt thereof, are present in a molar ratio of
~~between~~ about 1:14 ~~to 14:1~~ or about 2:7.

95-96. (Cancelled)